Approved Hospital Formulary
QR Code Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:

bupivacaine liposome

bupivacaine liposome
Brand names: Exparel
Form Strength
SUSPENSION, INJECTABLE 1.3% (13.3 mg/mL)

VIEW MORE Local Anesthetics
CLASS
720000

Additional Information:

In April 2022, the P&T Committee voted to remove liposomal bupivacaine (Exparel) from formulary, with a target implementation of August 1, 2022.

See the SBAR for more details. 


Last updated: Jun. 14, 2022







This site is intended for the staff of Legacy Health.
While others may view accessible pages, Legacy Health makes no warranty, express or implied,
as to the use of this information outside of Legacy Health.